查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1974019

癌症免疫疗法市场分析及预测（至2035年）：类型、产品、技术、应用、最终用户、模式、阶段、功能、解决方案

Cancer Immunotherapy Market Analysis and Forecast to 2035: Type, Product, Technology, Application, End User, Mode, Stage, Functionality, Solutions
出版日期: | 出版商: Global Insight Services | 英文 356 Pages | 商品交期: 3-5个工作天内

价格
简介目录

癌症免疫疗法市场预计将从2024年的2,286亿美元成长到2034年的5,423亿美元，复合年增长率约为9%。癌症免疫疗法市场涵盖利用和增强免疫系统自身攻击癌症能力的治疗方法，例如单株抗体、查核点抑制剂和癌症疫苗。该市场的成长动力来自技术进步、癌症发病率上升以及人们对个人化医疗日益增长的关注。创新正推动人们致力于提高疗效、减少副作用并提供持久的治疗效果，同时专注于研究和临床试验，以拓展治疗方法应用范围。

癌症免疫疗法市场正经历强劲成长，这主要得益于个人化医疗和标靶治疗的进步。单株抗体凭藉其靶向癌细胞的特异性和高效性，在疗效方面占据主导地位。查核点抑制剂能够增强免疫系统对抗癌症的能力，其疗效也排名第二。过继性细胞移植疗法，包括CAR-T细胞疗法，正作为变革性疗法崭露头角，并具有巨大的未来应用潜力。疫苗，尤其是治疗性癌症疫苗，因其在预防癌症復发方面的潜力而备受关注。细胞激素虽然并非主导因素，但仍在促进免疫反应中发挥辅助作用。生物标记和伴随诊断的整合正在提高治疗的精确度，并推动市场进一步扩张。持续的研发投入和策略合作对于在这个充满活力的环境中探索新机会、确保永续成长和创新至关重要。

市场区隔
类型 单株抗体、查核点抑制剂、癌症疫苗、细胞激素、过继性细胞疗法、溶瘤病毒疗法、双特异性抗体、免疫查核点调节剂
产品 治疗性抗体、免疫系统调节剂、细胞疗法、查核点阻断剂、癌症疫苗、溶瘤病毒、细胞激素
科技 基因编辑、CRISPR、CAR-T细胞疗法、TCR疗法、单株抗体技术、奈米技术、双特异性抗体技术
目的 肺癌、乳癌、大肠癌、黑色素瘤、摄护腺癌、白血病、淋巴瘤
最终用户 医院、癌症研究机构、诊所、生物製药公司、学术研究机构
模式 静脉注射、口服、皮下注射、肌肉注射
步 临床试验、商业化、临床前阶段。
功能 免疫活化、免疫抑制、免疫调节
解决方案 个人化免疫疗法、联合治疗、标靶治疗

市场概况：

癌症免疫疗法市场充满活力，创新定价策略和新治疗方法的推出推动了市场份额的显着变化。新产品的不断上市正在重塑竞争格局，并创造一个有利于成长和发展的环境。各公司正利用其先进的研发能力进行策略性布局，以抓住新的机会。旨在提高治疗效果和扩大市场的策略联盟和伙伴关係关係进一步加速了这一发展势头。在这种竞争环境下，主要企业正在进行严格的标竿分析，以保持其竞争优势。监管影响至关重要，严格的指导方针界定了市场准入和永续性。全球法规结构各不相同，北美和欧洲制定的严格标准影响全球标准。亚太地区正崛起为一个充满潜力的市场，这得益于有利的监管改革和不断增长的医疗保健投资。竞争与监管的相互作用正在塑造癌症免疫疗法市场的发展轨迹，为创新和成长提供了沃土。

主要趋势和驱动因素：

癌症免疫疗法市场正经历强劲成长，这主要得益于技术进步和研发投入的增加。关键趋势包括：针对个别患者情况量身定制的个人化免疫疗法的开发，从而改善治疗效果；联合治疗的兴起，透过整合多种治疗方法来增强疗效，也是一大趋势；此外，对肿瘤微环境的深入了解正在推动标靶治疗的创新；监管支持的加强和核准流程的加速正在加速新治疗方法进入市场；全球癌症发病率的上升以及对更有效治疗方法的未满足需求等因素也推动了市场增长；此外，医疗服务提供者和患者对免疫疗法的认知度和接受度不断提高，也促进了市场发展。新兴市场医疗基础设施正在发展，对先进疗法的需求不断增长，这些地区蕴藏着许多机会。投资最尖端科技并寻求策略合作的公司将能够更好地掌握这些趋势，预计癌症免疫疗法市场将持续成长。

压制与挑战：

癌症免疫疗法市场面临许多重大限制与挑战。其中一项主要挑战是治疗费用高昂。这不仅限制了许多患者的治疗机会，也给医疗保健系统带来了沉重的经济负担。这些治疗方法之所以价格昂贵，是因为它们需要大量的研发投入。监管障碍也是一大挑战。新型免疫疗法的严格核准流程会延缓其上市时间并增加成本。此外，癌症免疫疗法的作用机制复杂，难以预测患者的治疗反应，导致治疗结果有差异。另一项挑战是用于患者筛选的生物标记数量有限。这限制了识别最有可能从特定治疗方法中获益的患者的能力，从而降低了疗法的有效性。此外，该市场还面临来自更成熟、更广泛接受的传统癌症疗法（如化疗和放射线治疗）的竞争。最后，需要提高大众和专业人士的认知度。对免疫疗法潜在益处的认识不足会阻碍其推广应用和融入标准治疗方案。

目录

第一章：执行摘要

第二章 市集亮点

第三章 市场动态

  • 宏观经济分析
  • 市场趋势
  • 市场驱动因素
  • 市场机会
  • 市场限制因素
  • 复合年均成长率：成长分析
  • 影响分析
  • 新兴市场
  • 技术蓝图
  • 战略框架

第四章：细分市场分析

  • 市场规模及预测：依类型
    • 单株抗体
    • 查核点抑制剂
    • 癌症疫苗
    • 细胞激素
    • 过继性细胞疗法
    • 溶瘤病毒疗法
    • 双特异性抗体
    • 免疫查核点调节剂
  • 市场规模及预测：依产品划分
    • 治疗性抗体
    • 免疫系统调节剂
    • 细胞疗法
    • 查核点抑制
    • 癌症疫苗
    • 溶瘤病毒
    • 细胞激素
  • 市场规模及预测：依技术划分
    • 基因编辑
    • CRISPR
    • CAR-T细胞疗法
    • TCR疗法
    • 单株抗体技术
    • 奈米科技
    • 双特异性抗体技术
  • 市场规模及预测：依应用领域划分
    • 肺癌
    • 乳癌
    • 结肠癌
    • 黑色素瘤
    • 摄护腺癌
    • 白血病
    • 淋巴瘤
  • 市场规模及预测：依最终用户划分
    • 医院
    • 癌症研究机构
    • 诊所
    • 生物製药公司
    • 学术研究机构
  • 市场规模及预测：按模式
    • 静脉注射
    • 口服
    • 皮下注射
    • 肌肉内注射
  • 市场规模及预测：依阶段划分
    • 临床试验
    • 市售
    • 临床前阶段
  • 市场规模及预测：依功能划分
    • 免疫活化
    • 免疫抑制
    • 免疫调节
  • 市场规模及预测：按解决方案划分
    • 个人化免疫疗法
    • 联合治疗
    • 标靶治疗

第五章 区域分析

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲
  • 亚太地区
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳洲
    • 台湾
    • 亚太其他地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 义大利
    • 其他欧洲国家
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非
    • 撒哈拉以南非洲
    • 其他中东和非洲地区

第六章 市场策略

  • 供需差距分析
  • 贸易和物流限制
  • 价格、成本和利润率趋势
  • 市场渗透率
  • 消费者分析
  • 监管概述

第七章 竞争讯息

  • 市场定位
  • 市场占有率
  • 竞争基准
  • 主要企业的策略

第八章：公司简介

  • Adaptimmune Therapeutics
  • Immunocore
  • Iovance Biotherapeutics
  • Fate Therapeutics
  • Kite Pharma
  • Jounce Therapeutics
  • Replimune Group
  • Compugen
  • Agenus
  • OncoSec Medical
  • CureVac
  • Neon Therapeutics
  • BioNTech
  • Tessa Therapeutics
  • Argenx

第九章 关于我们

简介目录
Product Code: GIS33693

Cancer Immunotherapy Market is anticipated to expand from $228.6 billion in 2024 to $542.3 billion by 2034, growing at a CAGR of approximately 9%. The Cancer Immunotherapy Market encompasses treatments that harness and enhance the innate powers of the immune system to combat cancer, including monoclonal antibodies, checkpoint inhibitors, and cancer vaccines. This market is driven by technological advancements, a rising prevalence of cancer, and an increasing focus on personalized medicine. Innovations aim to improve efficacy, reduce side effects, and offer durable responses, with a strong emphasis on research and clinical trials to expand therapeutic applications.

The Cancer Immunotherapy Market is experiencing robust growth, propelled by advancements in personalized medicine and targeted therapies. The monoclonal antibodies segment leads in performance, owing to their specificity and effectiveness in targeting cancer cells. Checkpoint inhibitors, which enhance the immune system's ability to fight cancer, are also gaining prominence as the second highest performing segment. Adoptive cell transfer therapies, including CAR-T cell therapies, are emerging as a transformative approach, offering substantial promise for future applications. Vaccines, particularly therapeutic cancer vaccines, are witnessing increased interest due to their potential to prevent cancer recurrence. Cytokines, although less dominant, continue to play a supportive role in boosting immune responses. The integration of biomarkers and companion diagnostics is enhancing treatment precision, driving further market expansion. Continuous research and development, coupled with strategic collaborations, are pivotal in unlocking new opportunities within this dynamic landscape, ensuring sustained growth and innovation.

Market Segmentation
TypeMonoclonal Antibodies, Checkpoint Inhibitors, Cancer Vaccines, Cytokines, Adoptive Cell Therapy, Oncolytic Virus Therapy, Bispecific Antibodies, Immune Checkpoint Modulators
ProductTherapeutic Antibodies, Immune System Modulators, Cell Therapies, Checkpoint Blockade, Cancer Vaccines, Oncolytic Viruses, Cytokines
TechnologyGene Editing, CRISPR, CAR-T Cell Therapy, TCR Therapy, Monoclonal Antibody Technology, Nanotechnology, Bi-specific Antibody Technology
ApplicationLung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Leukemia, Lymphoma
End UserHospitals, Cancer Research Institutes, Clinics, Biopharmaceutical Companies, Academic and Research Institutes
ModeIntravenous, Oral, Subcutaneous, Intramuscular
StageClinical Trials, Commercialized, Preclinical
FunctionalityImmune Activation, Immune Suppression, Immune Modulation
SolutionsPersonalized Immunotherapy, Combination Therapies, Targeted Therapy

Market Snapshot:

The Cancer Immunotherapy Market is witnessing a dynamic landscape with a significant shift in market share, driven by innovative pricing strategies and the introduction of novel therapies. The continuous influx of new product launches is reshaping the competitive scenario, fostering an environment ripe for growth and development. Companies are strategically positioning themselves to capture emerging opportunities by leveraging advanced research and development capabilities. This momentum is further propelled by strategic collaborations and partnerships aimed at enhancing therapeutic efficacy and expanding market reach. In the competitive arena, key players are engaging in rigorous benchmarking to maintain their competitive edge. Regulatory influences play a pivotal role, with stringent guidelines dictating market entry and sustainability. The global landscape is characterized by a diverse regulatory framework, with North America and Europe setting stringent benchmarks that influence global standards. Asia-Pacific is emerging as a lucrative market, driven by favorable regulatory reforms and increased healthcare investments. The interplay of competition and regulation shapes the trajectory of the Cancer Immunotherapy Market, offering a fertile ground for innovation and growth.

Geographical Overview:

The cancer immunotherapy market is flourishing globally, with notable regional distinctions. North America leads, driven by substantial R&D investments and a high prevalence of cancer cases. The region's advanced healthcare infrastructure and robust biotech industry further propel market growth. Europe follows, with strong governmental support for cancer research and increasing adoption of innovative therapies. The region's focus on personalized medicine enhances its market position. In Asia Pacific, rapid expansion is observed, fueled by rising cancer incidences and growing healthcare expenditures. Countries like China and India emerge as key growth pockets, investing heavily in biotechnology and healthcare advancements. Latin America and the Middle East & Africa present promising opportunities. In these regions, increasing awareness and improving healthcare systems foster growth. Brazil and South Africa, in particular, are witnessing significant investments in cancer treatment infrastructure, recognizing the potential of immunotherapy in improving patient outcomes. These emerging markets are poised for substantial expansion in the coming years.

Key Trends and Drivers:

The Cancer Immunotherapy Market is experiencing robust growth fueled by technological advancements and increased investment in research and development. Key trends include the development of personalized immunotherapies tailored to individual patient profiles, enhancing treatment efficacy. The rise of combination therapies is another significant trend, offering improved outcomes by integrating multiple modalities. Furthermore, the expanding understanding of tumor microenvironments is driving innovation in targeted therapies. Increased regulatory support and expedited approval processes are accelerating market entry for novel treatments. Drivers include the growing prevalence of cancer worldwide and the unmet need for more effective therapies. Additionally, the market is benefiting from heightened awareness and acceptance of immunotherapy among healthcare providers and patients. Opportunities abound in emerging markets where healthcare infrastructure is improving, and demand for advanced treatments is rising. Companies investing in cutting-edge technologies and strategic collaborations are well-positioned to capitalize on these trends, ensuring sustained growth in the Cancer Immunotherapy Market.

Restraints and Challenges:

The cancer immunotherapy market encounters several significant restraints and challenges. One primary challenge is the high cost of treatment, which limits accessibility for many patients and places a financial burden on healthcare systems. These therapies often require substantial investment in research and development, leading to elevated prices. Regulatory hurdles also pose a significant challenge. The rigorous approval processes for new immunotherapies can delay market entry and increase costs. Furthermore, the complexity of cancer immunotherapy mechanisms makes it difficult to predict patient responses, leading to variable treatment outcomes. Another challenge is the limited availability of biomarkers for patient selection. This limits the ability to identify individuals who would benefit most from specific therapies, reducing treatment efficacy. Additionally, the market faces competition from traditional cancer treatments, such as chemotherapy and radiation, which are more established and widely accepted. Finally, there is a need for better public and professional awareness. The lack of understanding about immunotherapy's potential benefits can hinder its adoption and integration into standard care practices.

Key Players:

Adaptimmune Therapeutics, Immunocore, Iovance Biotherapeutics, Fate Therapeutics, Kite Pharma, Jounce Therapeutics, Replimune Group, Compugen, Agenus, OncoSec Medical, CureVac, Neon Therapeutics, BioNTech, Tessa Therapeutics, Argenx

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Technology
  • 2.4 Key Market Highlights by Application
  • 2.5 Key Market Highlights by End User
  • 2.6 Key Market Highlights by Mode
  • 2.7 Key Market Highlights by Stage
  • 2.8 Key Market Highlights by Functionality
  • 2.9 Key Market Highlights by Solutions

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Monoclonal Antibodies
    • 4.1.2 Checkpoint Inhibitors
    • 4.1.3 Cancer Vaccines
    • 4.1.4 Cytokines
    • 4.1.5 Adoptive Cell Therapy
    • 4.1.6 Oncolytic Virus Therapy
    • 4.1.7 Bispecific Antibodies
    • 4.1.8 Immune Checkpoint Modulators
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Therapeutic Antibodies
    • 4.2.2 Immune System Modulators
    • 4.2.3 Cell Therapies
    • 4.2.4 Checkpoint Blockade
    • 4.2.5 Cancer Vaccines
    • 4.2.6 Oncolytic Viruses
    • 4.2.7 Cytokines
  • 4.3 Market Size & Forecast by Technology (2020-2035)
    • 4.3.1 Gene Editing
    • 4.3.2 CRISPR
    • 4.3.3 CAR-T Cell Therapy
    • 4.3.4 TCR Therapy
    • 4.3.5 Monoclonal Antibody Technology
    • 4.3.6 Nanotechnology
    • 4.3.7 Bi-specific Antibody Technology
  • 4.4 Market Size & Forecast by Application (2020-2035)
    • 4.4.1 Lung Cancer
    • 4.4.2 Breast Cancer
    • 4.4.3 Colorectal Cancer
    • 4.4.4 Melanoma
    • 4.4.5 Prostate Cancer
    • 4.4.6 Leukemia
    • 4.4.7 Lymphoma
  • 4.5 Market Size & Forecast by End User (2020-2035)
    • 4.5.1 Hospitals
    • 4.5.2 Cancer Research Institutes
    • 4.5.3 Clinics
    • 4.5.4 Biopharmaceutical Companies
    • 4.5.5 Academic and Research Institutes
  • 4.6 Market Size & Forecast by Mode (2020-2035)
    • 4.6.1 Intravenous
    • 4.6.2 Oral
    • 4.6.3 Subcutaneous
    • 4.6.4 Intramuscular
  • 4.7 Market Size & Forecast by Stage (2020-2035)
    • 4.7.1 Clinical Trials
    • 4.7.2 Commercialized
    • 4.7.3 Preclinical
  • 4.8 Market Size & Forecast by Functionality (2020-2035)
    • 4.8.1 Immune Activation
    • 4.8.2 Immune Suppression
    • 4.8.3 Immune Modulation
  • 4.9 Market Size & Forecast by Solutions (2020-2035)
    • 4.9.1 Personalized Immunotherapy
    • 4.9.2 Combination Therapies
    • 4.9.3 Targeted Therapy

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Technology
      • 5.2.1.4 Application
      • 5.2.1.5 End User
      • 5.2.1.6 Mode
      • 5.2.1.7 Stage
      • 5.2.1.8 Functionality
      • 5.2.1.9 Solutions
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Technology
      • 5.2.2.4 Application
      • 5.2.2.5 End User
      • 5.2.2.6 Mode
      • 5.2.2.7 Stage
      • 5.2.2.8 Functionality
      • 5.2.2.9 Solutions
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Technology
      • 5.2.3.4 Application
      • 5.2.3.5 End User
      • 5.2.3.6 Mode
      • 5.2.3.7 Stage
      • 5.2.3.8 Functionality
      • 5.2.3.9 Solutions
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Technology
      • 5.3.1.4 Application
      • 5.3.1.5 End User
      • 5.3.1.6 Mode
      • 5.3.1.7 Stage
      • 5.3.1.8 Functionality
      • 5.3.1.9 Solutions
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Technology
      • 5.3.2.4 Application
      • 5.3.2.5 End User
      • 5.3.2.6 Mode
      • 5.3.2.7 Stage
      • 5.3.2.8 Functionality
      • 5.3.2.9 Solutions
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Technology
      • 5.3.3.4 Application
      • 5.3.3.5 End User
      • 5.3.3.6 Mode
      • 5.3.3.7 Stage
      • 5.3.3.8 Functionality
      • 5.3.3.9 Solutions
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Technology
      • 5.4.1.4 Application
      • 5.4.1.5 End User
      • 5.4.1.6 Mode
      • 5.4.1.7 Stage
      • 5.4.1.8 Functionality
      • 5.4.1.9 Solutions
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Technology
      • 5.4.2.4 Application
      • 5.4.2.5 End User
      • 5.4.2.6 Mode
      • 5.4.2.7 Stage
      • 5.4.2.8 Functionality
      • 5.4.2.9 Solutions
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Technology
      • 5.4.3.4 Application
      • 5.4.3.5 End User
      • 5.4.3.6 Mode
      • 5.4.3.7 Stage
      • 5.4.3.8 Functionality
      • 5.4.3.9 Solutions
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Technology
      • 5.4.4.4 Application
      • 5.4.4.5 End User
      • 5.4.4.6 Mode
      • 5.4.4.7 Stage
      • 5.4.4.8 Functionality
      • 5.4.4.9 Solutions
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Technology
      • 5.4.5.4 Application
      • 5.4.5.5 End User
      • 5.4.5.6 Mode
      • 5.4.5.7 Stage
      • 5.4.5.8 Functionality
      • 5.4.5.9 Solutions
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Technology
      • 5.4.6.4 Application
      • 5.4.6.5 End User
      • 5.4.6.6 Mode
      • 5.4.6.7 Stage
      • 5.4.6.8 Functionality
      • 5.4.6.9 Solutions
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Technology
      • 5.4.7.4 Application
      • 5.4.7.5 End User
      • 5.4.7.6 Mode
      • 5.4.7.7 Stage
      • 5.4.7.8 Functionality
      • 5.4.7.9 Solutions
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Technology
      • 5.5.1.4 Application
      • 5.5.1.5 End User
      • 5.5.1.6 Mode
      • 5.5.1.7 Stage
      • 5.5.1.8 Functionality
      • 5.5.1.9 Solutions
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Technology
      • 5.5.2.4 Application
      • 5.5.2.5 End User
      • 5.5.2.6 Mode
      • 5.5.2.7 Stage
      • 5.5.2.8 Functionality
      • 5.5.2.9 Solutions
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Technology
      • 5.5.3.4 Application
      • 5.5.3.5 End User
      • 5.5.3.6 Mode
      • 5.5.3.7 Stage
      • 5.5.3.8 Functionality
      • 5.5.3.9 Solutions
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Technology
      • 5.5.4.4 Application
      • 5.5.4.5 End User
      • 5.5.4.6 Mode
      • 5.5.4.7 Stage
      • 5.5.4.8 Functionality
      • 5.5.4.9 Solutions
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Technology
      • 5.5.5.4 Application
      • 5.5.5.5 End User
      • 5.5.5.6 Mode
      • 5.5.5.7 Stage
      • 5.5.5.8 Functionality
      • 5.5.5.9 Solutions
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Technology
      • 5.5.6.4 Application
      • 5.5.6.5 End User
      • 5.5.6.6 Mode
      • 5.5.6.7 Stage
      • 5.5.6.8 Functionality
      • 5.5.6.9 Solutions
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Technology
      • 5.6.1.4 Application
      • 5.6.1.5 End User
      • 5.6.1.6 Mode
      • 5.6.1.7 Stage
      • 5.6.1.8 Functionality
      • 5.6.1.9 Solutions
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Technology
      • 5.6.2.4 Application
      • 5.6.2.5 End User
      • 5.6.2.6 Mode
      • 5.6.2.7 Stage
      • 5.6.2.8 Functionality
      • 5.6.2.9 Solutions
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Technology
      • 5.6.3.4 Application
      • 5.6.3.5 End User
      • 5.6.3.6 Mode
      • 5.6.3.7 Stage
      • 5.6.3.8 Functionality
      • 5.6.3.9 Solutions
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Technology
      • 5.6.4.4 Application
      • 5.6.4.5 End User
      • 5.6.4.6 Mode
      • 5.6.4.7 Stage
      • 5.6.4.8 Functionality
      • 5.6.4.9 Solutions
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Technology
      • 5.6.5.4 Application
      • 5.6.5.5 End User
      • 5.6.5.6 Mode
      • 5.6.5.7 Stage
      • 5.6.5.8 Functionality
      • 5.6.5.9 Solutions

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Adaptimmune Therapeutics
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Immunocore
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Iovance Biotherapeutics
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Fate Therapeutics
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Kite Pharma
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Jounce Therapeutics
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Replimune Group
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Compugen
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Agenus
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 OncoSec Medical
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 CureVac
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Neon Therapeutics
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 BioNTech
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Tessa Therapeutics
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Argenx
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us